ELI LILLY & CO (LLY)
US5324571083 - Common Stock
ELI LILLY & CO
NYSE:LLY (5/16/2024, 2:02:00 PM)
775.455
-11.56 (-1.47%)
Company Profile
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The company is headquartered in Indianapolis, Indiana and currently employs 39,000 full-time employees. The firm discovers, develops, manufactures and markets products in the human pharmaceutical products segment. Its diabetes products include Basaglar, Humalog, Humulin, Jardiance, Mounjaro and Trulicity. Its oncology products consist of Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, and others. Its immunology products include Olumiant, Taltz, oral IL-17 inhibitors and others. Its neuroscience products include Cymbalta, Emgality, and Zyprexa. Its other therapies consist of Bamlanivimab and etesevimab, Bebtelovimab and Forteo. The company manufactures and distributes its products through facilities in the United States, including Puerto Rico, and other countries. The firm's subsidiary is POINT Biopharma Global Inc., which is a radiopharmaceutical company with a pipeline of clinical and preclinical stage radioligand therapies in development for the treatment of cancer. The firm's products are sold in over 110 countries.
Company Info
ELI LILLY & CO
Lilly Corporate Ctr, Drop Code 1094, Lilly Corporate Ctr
Indianapolis INDIANA 46285
P: 13172762000
CEO: David A. Ricks
Employees: 39000
Website: https://www.lilly.com/
LLY News
34 minutes ago - CNBCEli Lilly falls on a rival's obesity study — plus, we're removing 3 stocks from our watchlistEvery weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of trading.
42 minutes ago - QuartzEli Lilly says its experimental weekly insulin works just as well as traditional dailiesThe pharma giant known for its diabetes and weight loss medications shared results of it late-stage clinical trail its long-acting insulin efsitora
5 hours ago - Zacks Investment Research3 Drug Stocks to Watch on Raised 2024 Earnings & Sales GuidanceHere we discuss three drugmakers, Eli Lilly and Company (LLY), Novo Nordisk (NVO) and Merck (MRK), that have raised their earnings as well as sales guidance for 2024.
5 hours ago - CNBCRoche says weight loss drug shows promising results in early trialThe weekly injection helped patients with obesity lose 18.8% of their weight relative to those who received a placebo, after 24 weeks in the phase one trial.
7 hours ago - InvestorPlaceThe Dividend Investor’s Playbook: 3 Stocks for Consistent Cash Flow in 2024Dive into dividend stocks to buy, featuring Walmart's robust earnings and Eli Lilly's advances in pharmaceuticals and WMT's stock split.
8 hours ago - InvestorPlace7 Pharma Stocks Harnessing AI Brainpower for Big BreakthroughsAI continues to impact pharma stocks to buy in a major way, with these shares particularly well positioned as things heat up.
LLY Twits
Here you can normally see the latest stock twits on LLY, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
